Paul Edison

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5530773/publications.pdf

Version: 2024-02-01

109 papers	7,768 citations	116194 36 h-index	97045 71 g-index
117 all docs	117 docs citations	117 times ranked	10321 citing authors

#	Article	IF	Citations
1	Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. Molecular Psychiatry, 2022, 27, 2019-2029.	4.1	19
2	Brain Connectivity: A Comprehensive Journal in Clinical Neurology and Neuroscience. Brain Connectivity, 2022, 12, 3-5.	0.8	0
3	Brain Connectivity: A Clinical Neurology and Neuroscience Journal. Brain Connectivity, 2022, 12, 207-209.	0.8	0
4	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
5	Cerebrospinal Fluid sTREM2 Has Paradoxical Association with Brain Structural Damage Rate in Early- and Late-Stage Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 88, 117-126.	1.2	1
6	Brain Connectivity: A Journal of Clinical Neurology and Neuroscience. Brain Connectivity, 2022, 12, 299-301.	0.8	0
7	Prevalence of Depressive Symptoms in a Memory Clinic Cohort: A Retrospective Study. Journal of Alzheimer's Disease, 2022, 88, 1179-1187.	1.2	5
8	Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?. Nature Reviews Neurology, 2021, 17, 157-172.	4.9	1,242
9	Brain Connectivity: Advancing the Field of Neuroscience in the Era of COVID-19. Brain Connectivity, 2021, 11, 1-2.	0.8	0
10	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimerâ€™s subjects?. Alzheimer's Research and Therapy, 2021, 13, 47.	3.0	32
11	Brain Connectivity: Neurocognitive Involvement in COVID-19. Brain Connectivity, 2021, 11, 73-74.	0.8	0
12	Brain Connectivity and Alzheimer's Disease. Brain Connectivity, 2021, 11, 157-158.	0.8	0
13	Brain Connectivity and COVID-19. Brain Connectivity, 2021, 11, 251-252.	0.8	2
14	Microglial activation and bloodâ€“brain barrier leakage: chicken and egg?. Brain, 2021, 144, 1284-1285.	3.7	5
15	Re-emphasizing early Alzheimerâ€™s disease pathology starting in select entorhinal neurons, with a special focus on mitophagy. Ageing Research Reviews, 2021, 67, 101307.	5.0	62
16	Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. BMJ Neurology Open, 2021, 3, e000143.	0.7	46
17	Brain Connectivity and Neurological Sequalae in COVID-19. Brain Connectivity, 2021, 11, 331-332.	0.8	2
18	Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load. Molecular Psychiatry, 2021, 26, 5848-5855.	4.1	43

#	Article	IF	Citations
19	Long covidâ€”mechanisms, risk factors, and management. BMJ, The, 2021, 374, n1648.	3.0	946
20	Microglial activation and tau propagate jointly across Braak stages. Nature Medicine, 2021, 27, 1592-1599.	15.2	235
21	Call for Papers: Brain Connectivity. Brain Connectivity, 2021, 11, 595-595.	0.8	0
22	Brain Connectivity: Neuronal Damage in COVID-19. Brain Connectivity, 2021, 11, 405-407.	0.8	0
23	The role of amyloid PET in patient selection for extra-ventricular shunt insertion for the treatment of idiopathic normal pressure hydrocephalus: A pooled analysis. Journal of Clinical Neuroscience, 2021, 90, 325-331.	0.8	0
24	Brain Connectivity: Advances in Neuroimaging to Investigate COVID-19. Brain Connectivity, 2021, 11, 502-504.	0.8	0
25	The Differential Influence of Immune, Endocytotic, and Lipid Metabolism Genes on Amyloid Deposition and Neurodegeneration in Subjects at Risk of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 79, 127-139.	1.2	8
26	Brain Connectivity: Advancing Neuroscience and Neuroimaging. Brain Connectivity, 2021, 11, 596-598.	0.8	0
27	Brain Connectivity: Evaluating Neurological Complications in COVID-19. Brain Connectivity, 2021, 11, 692-694.	0.8	1
28	COVID-19, Network Dysfunction and Neurodegeneration. Brain Connectivity, 2021, 11, 785-787.	0.8	2
29	Neuroinflammation, microglial activation, and glucose metabolism in neurodegenerative diseases. International Review of Neurobiology, 2020, 154, 325-344.	0.9	12
30	Brain Connectivity in the Era of Artificial Intelligence. Brain Connectivity, 2020, 10, 397-398.	0.8	0
31	Brain Connectivity: Advances in Neurodegenerative Diseases. Brain Connectivity, 2020, 10, 251-252.	0.8	0
32	Brain Connectivity in Neuronal Integrity. Brain Connectivity, 2020, 10, 533-534.	0.8	0
33	Influence of cerebral glucose metabolic rate on cognitive function in Alzheimer's subjects. Alzheimer's and Dementia, 2020, 16, e045899.	0.4	0
34	Assessing the relationship between cognitive dysfunction and brain atrophy in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046004.	0.4	0
35	Tau formation is associated with microglial activation in more widespread cortical areas than is amyloid deposition. Alzheimer's and Dementia, 2020, 16, e046045.	0.4	0
36	Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral glucose metabolic rate in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046068.	0.4	0

#	Article	IF	Citations
37	Brain Connectivity: Structural and Functional Neuronal Integrity and Its Relationship with Pathological Substrates. Brain Connectivity, 2020, 10, 106-107.	0.8	1
38	The Invisible Enemy That Will Change the World Forever. Brain Connectivity, 2020, 10, 105-105.	0.8	1
39	Brain Connectivity: Neuronal Integrity and Its Relationship with Pathological Substrates. Brain Connectivity, 2020, 10, 51-52.	0.8	0
40	Brain Connectivity: Disrupted Structural and Functional Connectivityâ€"Cause or Effect?. Brain Connectivity, 2020, 10, 200-201.	0.8	0
41	Call for Special Issue Papers: Brain Connectivity Modalities in Alzheimer's Disease. Brain Connectivity, 2020, 10, 199-199.	0.8	0
42	Brain Connectivity: A Bidirectional Involvement of Structural Connectivity and Pathological Substrates in Neurodegeneration. Brain Connectivity, 2020, 10, 155-156.	0.8	0
43	Brain Connectivity: Structural Integrity and Brain Function. Brain Connectivity, 2020, 10, 1-2.	0.8	3
44	Brain Connectivity in Neurodegenerative Diseases. Brain Connectivity, 2020, 10, 465-466.	0.8	0
45	Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimerâ€™s Disease Subjects. Journal of Alzheimer's Disease, 2019, 70, 455-465.	1.2	6
46	A new perspective for advanced positron emission tomographyâ€"based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 2019, 15, 1081-1103.	0.4	16
47	Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography. Current Neurology and Neuroscience Reports, 2019, 19, 45.	2.0	57
48	Application of advanced brain positron emission tomographyâ€"based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	1.2	9
49	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâ€™s disease: study protocol for a randomised controlled trial (ELAD study). Trials, 2019, 20, 191.	0.7	127
50	Dynamic ¹¹C-PiB PET Shows Cerebrospinal Fluid Flow Alterations in Alzheimer Disease and Multiple Sclerosis. Journal of Nuclear Medicine, 2019, 60, 1452-1460.	2.8	64
51	Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology, 2019, 92, e1331-e1343.	1.5	69
52	A Note from Our New Editor-in-Chief. Brain Connectivity, 2019, 9, 593-593.	0.8	0
53	Brain Connectivity: The Basis of Neuronal Integrity. Brain Connectivity, 2019, 9, 743-744.	0.8	1
54	A Note from the Editor-in-Chief. Brain Connectivity, 2019, 9, 661-661.	0.8	0

#	Article	IF	Citations
55	Parametric mapping using spectral analysis for 11C-PBR28 PET reveals neuroinflammation in mild cognitive impairment subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1432-1441.	3.3	22
56	P2â€381: EVALUATION OF NOVEL ASTROCYTE MARKER [11C]BU99008 PET IN ALZHEIMER'S DISEASE: A DEMENTIA PLATFORM U.K. EXPERIMENTAL MEDICINE STUDY. Alzheimer's and Dementia, 2018, 14, P842.	0.4	0
57	O2â€15â€01: THE DIFFERENTIAL INFLUENCE OF IMMUNE, ENDOCYTOTIC AND LIPID METABOLISM GENES ON AMYLOID DEPOSITION AND NEURODEGENERATION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P659.	0.4	0
58	Systematic Analysis and Biomarker Study for Alzheimerâ€™s Disease. Scientific Reports, 2018, 8, 17394.	1.6	62
59	Role of Neuroinflammation in the Trajectory of Alzheimerâ€™s Disease and in vivo Quantification Using PET. Journal of Alzheimer's Disease, 2018, 64, S339-S351.	1.2	32
60	In vivo Imaging of Glial Activation in Alzheimer's Disease. Frontiers in Neurology, 2018, 9, 625.	1.1	71
61	Microglial activation correlates in vivo with both tau and amyloid in Alzheimerâ€™s disease. Brain, 2018, 141, 2740-2754.	3.7	143
62	Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimerâ€™s Disease Trajectory?. Journal of Alzheimer's Disease, 2018, 64, 981-993.	1.2	11
63	Imaging of Microglial Activation in Alzheimerâ€™s Disease by [11C]PBR28 PET. Methods in Molecular Biology, 2018, 1750, 323-339.	0.4	7
64	Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimerâ€™s Disease Trajectory?. Journal of Alzheimer's Disease, 2018, , 1-13.	1.2	0
65	Suspected non-Alzheimer's pathology â€“ Is it non-Alzheimer's or non-amyloid?. Ageing Research Reviews, 2017, 36, 20-31.	5.0	34
66	An early and late peak in microglial activation in Alzheimerâ€™s disease trajectory. Brain, 2017, 140, aww349.	3.7	245
67	Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimerâ€™s disease. Brain, 2017, 140, 2002-2011.	3.7	147
68	[P3â€“324]: DEMENTIA PLATFORM U.K. EXPERIMENTAL MEDICINE: HUMAN IN VIVO ASTROGLIAL ACTIVATION IN EARLY ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1073.	0.4	0
69	[O3â€“09â€“03]: MICROGLIAL ACTIVATION IS ASSOCIATED WITH HIGHER GREY MATTER DENSITY AND HIPPOCAMPAL VOLUME IN MCI SUBJECTS. Alzheimer's and Dementia, 2017, 13, P921.	0.4	1
70	Antidiabetic Drugs in Alzheimerâ€™s Disease: Mechanisms of Action and Future Perspectives. Journal of Diabetes Research, 2017, 2017, 1-7.	1.0	41
71	Alterations in Glucose Metabolism in Alzheimer's Disease. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2016, 10, 31-39.	0.7	53
72	O3â€02â€04: Does Neuroinflammation Predate Amyloid Formation in Subjects at Risk for Alzheimerâ€™s Disease?. Alzheimer's and Dementia, 2016, 12, P283.	0.4	0

#	Article	IF	Citations
73	Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimerâ€™s Disease and Parkinsonâ€™s Disease Dementia?. Journal of Alzheimer's Disease, 2016, 51, 1275-1289.	1.2	62
74	P1-283: An Early and Late Peak in Microglial Activation in Alzheimerâ€™s Disease Trajectory: A Longitudinal Pet Study. , 2016, 12, P527-P528.		1
75	P4-175: Increased [11C](R)PK11195-PET and Attenuated Cerebral Glucose Metabolism: A Common Theme in Neurodegenerative Diseases?. , 2016, 12, P1085-P1085.		0
76	Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimer's and Dementia, 2016, 12, 719-732.	0.4	1,076
77	Flutriciclamide (¹⁸F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. Journal of Nuclear Medicine, 2016, 57, 1753-1759.	2.8	93
78	Amyloid pathology and axonal injury after brain trauma. Neurology, 2016, 86, 821-828.	1.5	116
79	Imaging biomarkers in tauopathies. Parkinsonism and Related Disorders, 2016, 22, S26-S28.	1.1	23
80	P4-065: Role of neuroinflammation in Alzheimer's and parkinson's disease: [11C]PK11195 PET study. , 2015, 11, P792-P792.		0
81	Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimerâ€™s Disease and Other Neurodegenerative Diseases. CNS Drugs, 2015, 29, 1023-1039.	2.7	72
82	P2-128: Amyloid deposition, glucose metabolism, hippocampal volume, and cognitive decline in mild cognitive impairment: A longitudinal PET study. , 2015, 11, P532-P533.		0
83	O1-02-04: Glial activation influence on hippocampal volume and glucose metabolism in Alzheimer's disease and pdd. , 2015, 11, P127-P128.		0
84	Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. Alzheimer's and Dementia, 2015, 11, 1110-1120.	0.4	66
85	The Role of Neuroinflammation in Dementias. Current Neurology and Neuroscience Reports, 2015, 15, 17.	2.0	112
86	Carcinoid-associated Encephalopathy. Journal of Clinical Gastroenterology, 2015, 49, 353-354.	1.1	0
87	Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimerâ€™s disease. Brain, 2015, 138, 3685-3698.	3.7	102
88	Can Studies of Neuroinflammation in a TSPO Genetic Subgroup (HAB or MAB) Be Applied to the Entire AD Cohort?. Journal of Nuclear Medicine, 2015, 56, 707-713.	2.8	30
89	Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. Alzheimer's and Dementia, 2015, 11, 608.	0.4	161
90	The emerging agenda of stratified medicine in neurology. Nature Reviews Neurology, 2014, 10, 15-26.	4.9	30

#	Article	IF	Citations
91	Evaluation of neuroprotective effect of glucagonâ€like peptide 1 analogs using neuroimaging. Alzheimer's and Dementia, 2014, 10, S55-61.	0.4	36
92	The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimerâ€™s disease. Clinical Investigation, 2014, 4, 201-203.	0.0	0
93	Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. NeuroImage, 2013, 70, 423-433.	2.1	52
94	Microglia, Amyloid, and Glucose Metabolism in Parkinsonâ€™s Disease with and without Dementia. Neuropsychopharmacology, 2013, 38, 938-949.	2.8	202
95	Reference Region Automatic Extraction in Dynamic [¹¹C]PIB. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1725-1731.	2.4	20
96	11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldtâ€“Jakob disease: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 340-341.	0.9	8
97	Drug repositioning for Alzheimer's disease. Nature Reviews Drug Discovery, 2012, 11, 833-846.	21.5	239
98	Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?. NeuroImage, 2012, 60, 1716-1723.	2.1	36
99	Technical aspects of amyloid imaging for Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 25.	3.0	8
100	Improving recruitment of older people to research through good practice. Age and Ageing, 2011, 40, 659-665.	0.7	223
101	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain, 2011, 134, 293-300.	3.7	79
102	Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility. NeuroImage, 2009, 48, 329-338.	2.1	23
103	Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiology of Disease, 2008, 32, 412-419.	2.1	448
104	Novel Reference Region Model Reveals Increased Microglial and Reduced Vascular Binding of ¹¹C-(R)-PK11195 in Patients with Alzheimer's Disease. Journal of Nuclear Medicine, 2008, 49, 1249-1256.	2.8	81
105	A systematic comparison of kinetic modelling methods generating parametric maps for [11C]-(R)-PK11195. NeuroImage, 2007, 36, 28-37.	2.1	36
106	Reference and target region modeling of [11C]-(R)-PK11195 brain studies. Journal of Nuclear Medicine, 2007, 48, 158-67.	2.8	216
107	Amyloid load and cerebral atrophy in Alzheimer's disease: An11C-PIB positron emission tomography study. Annals of Neurology, 2006, 60, 145-147.	2.8	178
108	Parametric imaging of [11C]PIB studies using spectral analysis. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S590-S590.	2.4	1

#	Article	IF	Citations
109	Correlation of regional cerebral amyloid load in Alzheimer's disease, measured with [11C]-PIB pet using spectral analysis and tissue uptake ratios, with Performance on recognition memory tests. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S591-S591.	2.4	1